• 2000.09—2004.06  华中农业大学生物科学专业本科生

• 2005.09—2012.01  复旦大学生物化学与分子生物学专业博士研究

• 2012.03—2014.03  复旦大学化学流动站博士后研究员

• 2014.03—2019.03  美国斯坦福大学生物系博士后

• 2019.03—2021.01  美国斯坦福大学基础生命科学研究员

• 2021，上海市领军人才（海外）项目-第12批

• 肿瘤发生、发展、转移以及肿瘤耐药中的表观遗传机制

• 非组蛋白甲基化紊乱的恶性肿瘤调控机理，及临床药物靶点

• 课题组从表观遗传修饰的角度进行科学探索。借助CRISPR文库筛选，蛋白质组学，单细胞测序，生物信息学，蛋白芯片及体外活性鉴定平台等各种手段进行全方位研究。

• 2022-2025，国家自然科学基金面上项目，SETD5组蛋白修饰调控功能及非组蛋白甲基化活性在肺腺癌治疗耐药性中的作用研究 ，主持

• 2014-2016，国家自然科学基金青年项目，PRDM10甲基化组蛋白H3R2参与乳腺癌细胞的增殖调控，主持

• 2013-2016，中国博士后国际交流计划派出项目，主持

本科生课程：

• 大学生综合素养

1. Wang Z#, Hausmann S#, Lyu R, Li TM, Lofgren SM, Flores NM, Fuentes ME, Caporicci M, Yang Z, Meiners MJ, Cheek MA, Howard SA, Zhang L, Elias JE, Kim MP, Maitra A, Wang H, Bassik MC, Keogh MC, Sage J, Gozani O*, Mazur PK*. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy, Cancer Cell. 2020 Jun 8;37(6):834-849.

2. Biggar KK, Wang Z, Li SS. SnapShot: Lysine Methylation beyond Histones. Mol Cell. 2017 Dec 7;68(5):1016-1016.

3. Shen H#, Xu W#, Guo R, Rong B, Gu L, Wang Z, He C, Zheng L, Hu X, Hu Z, Shao ZM, Yang P, Wu F, Shi YG, Shi Y*, Lan F*. Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex. Cell. 2016 Apr 7;165(2):331-342.

4. Ma C, Karwacki-Neisius V, Tang H, Li W, Shi Z, Hu H, Xu W, Wang Z, Kong L, Lv R, Fan Z, Zhou W, Yang P, Wu F, Diao J, Tan L, Shi YG, Lan F*, Shi Y*. Nono, a Bivalent Domain Factor, Regulates Erk Signaling and Mouse Embryonic Stem Cell Pluripotency. Cell Rep. 2016 Oct 18;17(4):997-1007.

5. Guo R#, Zheng L#, Park JW, Lv R, Chen H, Jiao F, Xu W, Mu S, Wen H, Qiu J, Wang Z, Yang P, Wu F, Hui J, Fu X, Shi X, Shi YG, Xing Y*, Lan F*, Shi Y*. BS69/ZMYND11 reads and connects histone H3.3 lysine 36 trimethylation-decorated chromatin to regulated pre-mRNA processing. Mol Cell. 2014 Oct 23;56(2):298-310.

6. Ma H#, Chen H#, Guo X#, Wang Z, Sowa ME, Zheng L, Hu S, Zeng P, Guo R, Diao J, Lan F, Harper JW, Shi YG, Xu Y*, Shi Y*. M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability. Proc Natl Acad Sci U S A. 2012 Mar 12;109(13):4828-4833.

7. Rajakumara E#, Wang Z#,  Ma H, Hu L, Chen H, Lin Y, Guo R, Wu F, Li H, Lan F, Shi YG, Xu Y, Patel DJ*, Shi Y*. PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression. Mol Cell. 2011 Jul 22;43(2):275-284. (#Co-first author).

8. Han S, Zhang HT, Wang Z, Xie Y, Tang R, Mao Y, Li Y.DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Eur J Hum Genet. 2006 Oct;14(10):1136-1144.

9. Han S, Zhang S, Zhang W, Li R, Li Y, Wang Z, Xie Y, Mao Y.CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis.Hum Immunol. 2006 Aug;67(8):618-626.

10. Peng Xu#, Lan Zhang#, Yao Xiao#, Wei Li#, Zhiqiang Hu#, Rukui Zhang, Jin Li, Feizhen Wu, Yanping Xi, Qingping Zou, Zhentian Wang, Rui Guo, Honghui Ma, Shihua Dong, Min Xiao, Zhicong Yang, Xiaoguang Ren, Chaochun Wei* and Wenqiang Yu*, UHRF1 regulates alternative splicing by interacting with splicing factors and U snRNAs in a H3R2me involved manner, Hum Mol Genet. 2021 Nov 1;30 (22):2110-2122